Growth and use of methylphenidate in the child and adolescent population: Systematic review

Marília Guimarães de Sousa Jota and Analía Claudia Sabattini

SCT Proceedings in Interdisciplinary Insights and Innovations, 2023, vol. 1, 10.56294/piii2023174

Abstract: Methylphenidate (MFD) is a drug widely used in the world for the treatment of ADHD (attention deficit hyperactivity disorder). Several adverse effects have been reported with its use, such as growth retardation in the pediatric population, but the available scientific evidence is limited, and a consensus has not yet been reached to determine whether MFD really produces such an effect. A search in PubMed, Cochrane Library, academic Google and a synthesis of available evidence on the growth and use of methylphenidate in the child and adolescent population were analyzed through a Systematic Review type study where previous publications were analyzed. 07 articles have been selected to evaluate the effect of methylphenidate on growth in infants and adolescents to assess the impact of growth in such a population. It is concluded that there is insufficient evidence on the affectation of growth, there are no long-term studies to confirm this action, in such a way that it cannot be affirmed that there is an important weight loss in the growth of children and adolescents

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:procee:v:1:y:2023:i::p:1056294piii2023174:id:1056294piii2023174

Access Statistics for this article

More articles in SCT Proceedings in Interdisciplinary Insights and Innovations from AG Editor (Argentina)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().